Best mRNA / LNP CDMOs in Asia

← All mRNA/LNP CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

For Asia-manufactured mrna / lnp programs, ProBio, ST Pharm, and Samsung Biologics lead CDMO Signal's ranking of mrna / lnp CDMOs with confirmed Asian manufacturing sites. Filtered from the global directory of 36 scored mrna / lnp CDMOs to 5 with Asia-Pacific facility presence. Asian CDMOs cover a range of regulatory jurisdictions — PMDA (Japan), NMPA (China), MFDS (South Korea), CDSCO (India) — each with distinct requirements. For sponsors supplying US and EU markets, cross-jurisdictional regulatory posture (FDA and EMA/MHRA inspection history on Asian facilities) is typically the qualifying signal. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

mRNA and lipid nanoparticle (LNP) manufacturing scaled rapidly after COVID-19 vaccines and now supports therapeutics across rare disease, oncology, and infectious disease. The platform pairs IVT mRNA synthesis with LNP formulation — two distinct capability sets.

Choosing an mRNA/LNP CDMO depends on IVT scale, template strategy (linearized plasmid vs PCR), LNP formulation and microfluidics, and cold-chain handling. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 0 NAI (no action), 1 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: Denmark (3), Italy (3), United States (2), Belgium (2), Czechia (2).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	PBI ProBio Taipei, Taiwan	78.1	100.0	0 insp · 9 GMP	—	0 programs
2	SP ST Pharm Seoul, South Korea	72.8	88.1	2 insp · 4 GMP	—	0 programs
3	SB Samsung Biologics Incheon, South Korea, Rockville, Maryland, USA	61.5	—	—	Available	0 programs
4	CoJourney Inc. Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)	60.0	—	—	Limited	0 programs
5	RR RiboBio Guangzhou, CN	59.0	—	—	—	0 programs
—	BioCina Adelaide, Australia	Profiled	—	—	—	0 programs
—	ARCALIS, Inc. Minamisoma, Fukushima, Japan	Profiled	—	—	—	0 programs
—	Sai Life Sciences Hyderabad, India	Profiled	—	—	—	0 programs
—	AsymBio Shanghai, China	Profiled	—	—	—	0 programs
—	Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site) Indianapolis, IN	Profiled	—	—	—	0 programs
—	Southern RNA Brisbane, Australia	Profiled	—	—	—	0 programs
—	IDT Australia Boronia, Australia	Profiled	—	—	—	0 programs
—	Moderna Technology Centre – Melbourne (mRNA Victoria) Melbourne, Australia	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a mRNA / LNP CDMO

IVT mRNA synthesis

Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.

LNP formulation

LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.

Plasmid / starting material

mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.

Cold chain & stability

mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.

Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)

Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.

Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?

Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.

Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)

Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.

mRNA / LNP CDMOs — Frequently Asked Questions

Who are the top mRNA / LNP CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked mRNA / LNP CDMOs include ProBio, ST Pharm, Samsung Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many mRNA / LNP CDMOs have FDA inspection records?

CDMO Signal tracks 1 mRNA / LNP CDMO with FDA inspection records and 13 EMA/MHRA GMP certificates across the group.

What should I look for in an mRNA / LNP CDMO?

Look for proven IVT mRNA synthesis at your scale, LNP formulation via microfluidics, a clear template/plasmid supply strategy, cold-chain capability, and a clean FDA and EMA/MHRA record.

Do mRNA CDMOs also make the LNP and plasmid?

Capabilities vary. Some CDMOs offer end-to-end IVT mRNA, LNP formulation, and GMP plasmid; others specialize in one step and coordinate partners. Check each profile's modality coverage above.

Related modalities

Plasmid DNA CDMOs Lentiviral Vector CDMOs AAV / Gene Therapy CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC